BCPC · Balchem Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings from operations for Animal Nutrition and Health segment non-GAAP | $5.6M | Q2 2026 | — |
| Adjusted earnings from operations for Human Nutrition and Health segment non-GAAP | $45.9M | Q2 2026 | — |
| Adjusted earnings from operations for Specialty Products segment non-GAAP | $13.9M | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $77.9M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA $71.37M
+$5.92M Non-cash compensation expense related to equity awards
+$22K Transaction and integration costs (2)
+$631K Nonqualified deferred compensation plan expense (3)
+$0K Restructuring costs (4)
= Adjusted EBITDA $77.94M
|
|||
| Adjusted net earnings per common share non-GAAP | $1.49 | Q2 2026 | — |
| Free cash flow non-GAAP | $36.2M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 46.71M
-10.48M Capital expenditures and proceeds from the sale of assets
= Free cash flow 36.23M
|
|||
| Leverage ratio | 0.3 | As of June 30, 2026 | — |
| Net debt | $88.8M | As of June 30, 2026 | — |
| Adjusted earnings per share non-GAAP | $5.15 | full year 2025 | — |
| Adjusted net earnings non-GAAP | $167.9M | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCPC
this stock
Balchem Corp
|
$5.69B | +16.4% | +13.6% | 35.1 | 1.7% |
|
LIN
Linde PLC
|
$222.53B | +13.2% | +3.0% | 31.1 | 1.2% |
|
AIQUF
L Air Liquide SA /Fi
|
$126.61B | +4.0% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$87.44B | +10.8% | +2.1% | 33.2 | 2.6% |
|
ECL
Ecolab Inc.
|
$77.40B | +5.2% | +2.2% | 37.1 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCPC | -0.5% | +9.3% | +1.6% | +6.5% | +16.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.9% | +4.8% | -12.2% | +2.6% | +2.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.